Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
Aykut Cilli, Ismail Hanta, Fatih Uzer, Funda Coskun, Can Sevinc, Pelin Pınar Deniz, Mehmet Parlak, Ersoy Altunok, Kemal Can Tertemiz, Ahmet Ursavas
Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Background: There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) infection in patients with idiopathic pulmonary fibrosis (IPF). The objective of this study is to describe the characteristics and outcomes of IPF patients confirmed COVID-19 infection. Methods: In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with known IPF and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records. Results: Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65 § 10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was significantly associated with lower DLCO/VA, long term oxygen therapy and consolidation finding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated with hospitalization or mortality. Conclusions: IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain key to protect IPF patients.
Conflict of Interest None.
References
Aloufi, Traboulsi, Ding, Fonseca, Nair et al., Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: the forgotten cell in COVID-19, Am J Physiol Lung Cell Mol Physiol,
doi:10.1152/ajplung.00455.2020Drake, Docherty, Harrison, Quint, Adamali et al., Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study, Am J Respir Crit Care Med,
doi:10.1164/rccm.202007-2794OCEsposito, Menon, Ghosh, Putman, Fredenburgh et al., Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study, Am J Respir Crit Care Med,
doi:10.1164/rccm.202006-2441LEGallay, Uzunhan, Borie, Lazor, Rigaud et al., Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease, Am J Respir Crit Care Med,
doi:10.1164/rccm.202007-2638LEHuang, Zhang, Chen, Zhang, Wei et al., Clinical characteristics of COVID-19 in patients with pre-existing ILD: a retrospective study in a single center in Wuhan, China, J Med Virol,
doi:10.1002/jmv.26174Lee, Choi, Yang, Lee, Park et al., Interstitial lung disease increases susceptibility to and severity of COVID-19, Eur Respir J,
doi:10.1183/13993003.04125-2020Li, Liu, Hsu, Lin, Hsu et al., Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19, Part Fibre Toxicol,
doi:10.1186/s12989-021-00404-3Li, Wu, Wu, Guo, Chen et al., The clinical and chest CT features associated with severe and critical COVID-19 pneumonia, Invest Radiol,
doi:10.1097/RLI.0000000000000672Naqvi, Lakhani, Sohail, Maurer, Sofka et al., Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis, BMJ Open Respir Res,
doi:10.1136/bmjresp-2021-000969Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med,
doi:10.1111/joim.13091Raghu, Collard, Egan, Martinez, Behr et al., An Official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med,
doi:10.1164/rccm.2009-040GLRajasurya, Gunasekaran, Damarla, Kolluru, A Fatal case of coronavirus disease 2019 (COVID-19) in a patient with idiopathic pulmonary fibrosis, Cureus n,
doi:10.7759/cureus.8432Tuite, Fisman, Odutayo, Bobos, Allen et al., COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern, Ontario COVID-19 Science Advisory Table,
doi:10.47326/ocsat.2021.02.18.1.0Wong, Fidler, Marcoux, Johannson, Assayag et al., Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic, Chest,
doi:10.1016/j.chest.2020.04.019Ye, Zhang, Wang, Huang, Song, Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review, Eur Radiol,
doi:10.1007/s00330-020-06801-0Yuan, Yin, Tao, Tan, Hu, Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China, PLoS ONE,
doi:10.1371/journal.pone.0230548
